Showing results (11-20 of 25) with videos related to
Sort By:
Pageof 3
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 30, 2016
First-Line Afatinib versus Chemotherapy in Patients with Non-Small Cell Lung Cancer and Common Epidermal Growth Factor Receptor Gene Mutations and Brain MetastasesMartin Schuler, Yi-Long Wu, Vera Hirsh, et al.Lung Cancer (Amsterdam, Netherlands)|February 16, 2015
Phase II study of afatinib, an irreversible ErbB family blocker, in demographically and genotypically defined lung adenocarcinomaJacques De Grève, Teresa Moran, Marie-Pascale Graas, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 3, 2013
Symptom control and quality of life in LUX-Lung 3: a phase III study of afatinib or cisplatin/pemetrexed in patients with advanced lung adenocarcinoma with EGFR mutationsJames Chih-Hsin Yang, Vera Hirsh, Martin Schuler, et al.Clinical and Experimental Nephrology|April 20, 2024
Effects of empagliflozin in patients with chronic kidney disease from Japan: exploratory analyses from EMPA-KIDNEYMasaomi Nangaku, William G Herrington, Shinya Goto, et al.The Lancet. Oncology|January 21, 2014
Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trialYi-Long Wu, Caicun Zhou, Cheng-Ping Hu, et al.Breast Cancer Research : BCR|June 12, 2023
XENERA-1: a randomised double-blind Phase II trial of xentuzumab in combination with everolimus and exemestane versus everolimus and exemestane in patients with hormone receptor-positive/HER2-negative metastatic breast cancer and non-visceral diseasePeter Schmid, Javier Cortes, Ana Joaquim, et al.British Journal of Cancer|December 23, 2016
EGFR mutation detection in circulating cell-free DNA of lung adenocarcinoma patients: analysis of LUX-Lung 3 and 6Yi-Long Wu, Lecia V Sequist, Cheng-Ping Hu, et al.The Patient|November 28, 2017
Does EGFR Mutation Type Influence Patient-Reported Outcomes in Patients with Advanced EGFR Mutation-Positive Non-Small-Cell Lung Cancer? Analysis of Two Large, Phase III Studies Comparing Afatinib with Chemotherapy (LUX-Lung 3 and LUX-Lung 6)Yi-Long Wu, Vera Hirsh, Lecia V Sequist, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 3, 2013
Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutationsLecia V Sequist, James Chih-Hsin Yang, Nobuyuki Yamamoto, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 26, 2023
Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With <i>EGFR</i> MutationsLecia V Sequist, James Chih-Hsin Yang, Nobuyuki Yamamoto, et al.Pageof 3